Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958734 | 1.00 | GRK6 (0.34) | GRK6MEN1USP2PPARGKMT2A | |
| SCHEMBL9958738 | 1.00 | GRK6 (0.34) | GRK6MEN1USP2PPARGKMT2A | |
| SCHEMBL2903859 | 1.00 | GRK6 (0.34) | GRK6MEN1USP2PPARGKMT2A | |
| Hydrochloric Acid SCHEMBL5739950 | 0.98 | GRK6 (0.33) | GRK6MEN1USP2PPARGKMT2A | |
| Hydrochloric Acid SCHEMBL7477355 | 0.98 | GRK6 (0.33) | GRK6MEN1USP2PPARGKMT2A | |
| SCHEMBL27344588 | 0.98 | GRK6 (0.33) | GRK6MEN1USP2PPARGKMT2A | |
| Hydrochloric Acid SCHEMBL28741046 | 0.96 | GRK6 (0.32) | GRK6 | |
| SCHEMBL6300819 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL6300812 | 0.77 | — | — | |
| SCHEMBL30218263 | 0.70 | TRPA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2025-03-06 | — | — | US | claimed |
| EP-4463153-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | Eleusis Therapeutics US, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| CN-114276304-B | A process for preparing 1, 5-benzodiazepine derivatives as pharmaceutical intermediates containing fused rings | 南京苏亦欣医药科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118221679-A | Benzo [ b ] [1,4] diazepine [4,5-e ] tetrazole derivative and pharmaceutically acceptable salt, preparation method and application thereof | 常熟理工学院 | 2024-06-21 | — | — | CN | claimed |
| CN-116589417-B | method for green synthesis of medical intermediate 1, 5-benzodiazepine derivative | 安徽工业大学 | 2024-03-26 | — | — | CN | claimed |
| CN-117105934-A | Method for preparing benzodiazepine compound by selective hydrogenation | 石河子大学 | 2023-11-24 | — | — | CN | claimed |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2023-09-07 | — | — | US | claimed |
| CN-116589417-A | Method for green synthesis of medical intermediate 1, 5-benzodiazepine derivative | 安徽工业大学 | 2023-08-15 | — | — | CN | claimed |
| WO-2023137094-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2023-07-20 | — | — | WO | claimed |
| EP-4178569-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | Eleusis Therapeutics US, Inc. (US) | 2023-05-17 | — | — | EP | claimed |
| US-6413930-B1 | CONTROLLING EYE MOVEMENT | GLAXO WELLCOME SPA (IT) | 2002-07-02 | — | — | US | claimed |
| EP-0785788-B1 | USE OF CCK-B RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDERS | GLAXO WELLCOME SPA (IT) | 2001-12-12 | — | — | EP | claimed |
| CN-1307567-A | 1,5 benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2001-08-08 | — | — | CN | claimed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | claimed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | claimed |
| EP-0395323-B1 | Process for preparing 1,5-benzothiazepine derivatives | TANABE SEIYAKU CO (JP) | 1997-06-11 | — | — | EP | claimed |
| EP-0487155-A1 | Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides | EASTMAN KODAK COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| EP-0211429-A1 | 1,5-Benzodiazepine compounds | E.R. Squibb & Sons, Inc. (US) | 1987-02-25 | — | — | EP | claimed |
| US-4036649-A | Silver halide emulsion sensitized with a fused diazepine | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-07-19 | — | — | US | claimed |
| US-3984398-A | 1,5-Benzodiazepine-2,4-diones | ROUSSEL-UCLAF (FR) | 1976-10-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | SRI, PROC, PRDX6 | GRK6 3601/4885MEN1 4470/4885USP2 2834/4885 |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | PNN, HTR1B, GABBR1 | GRK6 980/4885MEN1 2910/4885USP2 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.